Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis
1 finding from 1 review
Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
1 finding from 1 review
Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tertiary outcome: prevention and treatment of other skin changes (number of feet being fissure‐ and callous‐free at 6 weeks) · skin changes caused by nerve damage in leprosy
It is very uncertain whether wax therapy changes tertiary outcome: prevention and treatment of other skin changes… compared with foot soaks (very low certainty).
1 finding from 1 review
Primary outcome: prevention of ulcer · skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with treatment · skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: quality of life · skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: acceptability of treatment · skin changes caused by nerve damage in leprosy
1 finding from 1 review
Cost of the intervention · skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
1 finding from 1 review
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).
1 finding from 1 review